Medical Care Technologies Inc (MDCE): "If" as "fact". You're a sorry skank...

StockItOut · 2025-03-28T21:11:59.0770000Z

"If" as "fact". You're a sorry skank. All you do is harass folks on iHub. Your post history proves it.

Play Episode

3min

Proactive - Interviews for investors

2D Photonics CEO discusses plans to scale up advanced graphene-based photonics technology

Frontier IP Group portfolio company 2D Photonics CEO Ben Jensen talked with Proactive's Stephen Gunnion about the company’s recent €25 million funding round and its plans to scale up its advanced graphene-based photonics technology. Jensen explained the growing demand for faster, more cost-effective data transmission solutions, driven by sectors such as AI and 5G. “What’s required today is ever faster data transmission at lower costs,” he said. According to Jensen, the new device architecture 2D Photonics has developed simplifies photonics design while significantly improving performance. This innovation is crucial for enabling higher bandwidth and lower power consumption across data networks. The funding will support the expansion of the leadership team and the development of pilot production capabilities. Jensen emphasized the importance of execution at this early stage, noting that the goal is to demonstrate the scalability of the technology for semiconductor foundries and ultimately reach high-volume manufacturing. He also discussed future applications, pointing to sectors such as space and defence, where rugged environments make traditional photonics challenging. In addition, the technology has relevance for Advanced Driver-Assistance Systems (ADAS), where rapid data transmission between sensors is critical for vehicle safety. Visit Proactive’s YouTube channel for more insightful interviews like this. Don’t forget to like this video, subscribe to our channel, and enable notifications so you never miss an update. #GraphenePhotonics #2DPhotonics #FrontierIPGroup #DataTransmission #SemiconductorTech #ADAS #SpaceTech #PhotonicsInnovation #GrapheneTech #DeepTechStartups #HighSpeedData #BenJensen #ProactiveInvestors

Proactive - Interviews for investors

NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate

NanoViricides Chief Financial Officer Meeta Vyas joined Steve Darling from Proactive to share updates on the company’s development of broad-spectrum antiviral therapeutics and its unique positioning amid global market uncertainty. Vyas emphasized that NanoViricides, headquartered in Shelton, Connecticut, conducts all of its research and development in-house, which insulates the company from international tariff fluctuations and supply chain disruptions. At the center of the company’s pipeline is NV-387, a broad-spectrum antiviral drug that differs from vaccines in both function and strategy. Rather than targeting specific viral strains, NV-387 works by mimicking the receptor sites used by over 90% of pathogenic viruses—including influenza, RSV, COVID-19, and smallpox. Vyas explained that this approach helps circumvent the problem of viral mutation, which often renders traditional vaccines less effective. “Regardless of how they mutate, they land on the same receptor site. So we copy the receptor site, which is invariant to mutation,” she said, underscoring the robustness of the NanoViricides platform. She also highlighted supportive regulatory developments in the U.S., noting that the new HHS administration has endorsed a more integrated approach to pandemic preparedness, which includes therapeutics like NV-387 as a key component. In light of recent USDA funding initiatives aimed at combating H5N1 avian flu, Vyas said the company is keen to explore applications of NV-387 in that space as well. Currently, NanoViricides is conducting a Phase 2 clinical trial targeting smallpox, following successful Phase 1 results with no reported adverse effects. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc NV387 #BroadSpectrumAntiviral #BiotechStocks #AntiviralTherapeutics #SmallpoxTreatment #BirdFlu #RSV #COVID19Treatment #ProactiveInvestors #PharmaInnovation #MeetaVyas #HHS #PandemicPreparedness

Proactive - Interviews for investors

Caledonia Mining sees big profit jump in 2024; welcomes gold's move above $3,000

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth talked with Proactive's Stephen Gunnion about the company’s strong 2024 financial performance and strategic priorities following the release of its latest results. Learmonth reported a “strong end to a reasonably good year,” with annual gold production reaching approximately 78,000 ounces—within guidance—supported by favourable pricing. He highlighted that “gross profit for the year was 77 million, compared to 41 million last year,” with adjusted earnings per share rising sharply from less than $0.10 in 2023 to nearly $1.30 in 2024. The results were delayed due to a technical accounting issue, with Learmonth explaining this stemmed from a deferred tax calculation error dating back to 2019. He stressed it had “no impact on our actual tax liabilities and tax payments.” On project development, the feasibility study for the Bilboes project has been extended to evaluate options that could significantly reduce capital costs. These include the potential to export concentrate and relocate the tailings facility, potentially lowering upfront investment needs. Exploration at both Blanket and Motapa returned positive results. Learmonth noted that the Blanket resource base has been extended, and early work at Motapa uncovered “exciting mineralisation” in new areas. With gold prices currently above $3,000 per ounce, the company is focused on maximising cash flow and investing further in Blanket and other revenue-generating opportunities. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #CaledoniaMining #GoldMining #MarkLearmonth #MiningStocks #GoldPrice #ZimbabweMining #BilboesProject #BlanketMine #MotapaExploration #InvestingInMining #MiningUpdate #ProactiveInvestors

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Followers	43
Posts	22158
Boards Moderated	0
Alias Born	01/04/2011

Volume:	-
Day Range:
Bid:	0.0008
Ask:	0.0011
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

MDCE Detailed Quote

Recent MDCE News

More MDCE News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent MDCE News

Go Ad-Free